• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Medicus Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    3/24/25 8:06:11 PM ET
    $MDCX
    Get the next $MDCX alert in real time by email
    Medicus Pharma Ltd.: Form 8-K - Filed by newsfilecorp.com

    false 2025-03-21 0001997296 Medicus Pharma Ltd. 0001997296 2025-03-21 2025-03-21 0001997296 exch:XNCM mdcx:CommonSharesNoParValueMember 2025-03-21 2025-03-21 0001997296 exch:XNCM mdcx:WarrantsEachExercisableForOneCommonShareAtAnExercisePriceOfFourPointSixFourPerShareMember 2025-03-21 2025-03-21

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ___________________________

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 21, 2025

    MEDICUS PHARMA LTD.
    (Exact name of registrant as specified in its charter)

    Ontario 001-42408 98-1778211
    (State or other jurisdiction (Commission (IRS Employer
    of incorporation) File Number) Identification No.)

    300 Conshohocken State Road, Suite 200
    Conshohocken, Pennsylvania, United States 19428
    (Address of principal executive offices) (ZIP Code)

    Registrant’s telephone number, including area code: (610) 540-7515

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class   Trading Symbols   Name of each exchange on which registered
    Common shares, no par value   MDCX   NASDAQ Capital Market
    Warrants, each exercisable for one common share at an exercise price of $4.64 per share   MDCXW   NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

    Emerging growth company ☑

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


    ​​Item 8.01 Other Events.

    On March 21, 2025, Odyssey Trust Company, as agent to Medicus Pharma Ltd. (the "Company"), filed an amendment (the "Amended Notice") to its previously filed Notice of Meeting and Record Date (the "Original Notice") with the Canadian securities authorities on SEDAR+, to cancel the Original Notice setting forth the meeting date for the Company's annual and special meeting of shareholders and the record date related to such meeting. A copy of the Amended Notice is filed as Exhibit 99.1 hereto.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.   Description
    99.1   (Amended) Notice of Meeting and Record Date
    104.1   Cover Page Interactive Data File (embedded within the inline XBRL document).



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.​

      MEDICUS PHARMA LTD.
         
         
      By: /s/ Raza Bokhari
      Name: Dr. Raza Bokhari
      Title: Executive Chairman and Chief Executive Officer

    ​Dated: March 24, 2025​


    Get the next $MDCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDCX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MDCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

    PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce topline results from its Phase 2 clinical study (SKNJCT-003) evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The Company believes the topline results are not only positive but decision-grade that should support an end of phase 2 (EOP2) meeting with the FDA in the first half of 2026 as well as accelerate partnering readiness. S

    3/5/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma To Participate in the 38th Annual Roth Conference

    PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will be participating in the 38th Annual Roth Conference, being held March 22-24, 2026, in Dana Point, California. Dr. Raza Bokhari, Executive Chairman & CEO of Medicus, will participate in a Fireside Chat hosted by Roth Capital Partners Managing Director and Senior Research Analyst Jonathan Aschoff. Dr. Bokhari will review the clinical development programs of the company, especially Skinject's potential effica

    3/3/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

    PHILADELPHIA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has received "study may proceed" clearance from the U.S. Food and Drug Administration (FDA) to initiate its Phase 2b dose-optimization study of Teverelix®, an investigational next generation long-acting GnRH antagonist, in men with advanced prostate cancer (APC). Teverelix® Clinical Trial Design in Advanced Prostate Cancer The Phase 2b study is an open-label trial enrolling 40 men with adv

    2/10/26 7:30:00 AM ET
    $MDCX

    $MDCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Smith Andrew Alasdair

    4 - Medicus Pharma Ltd. (0001997296) (Issuer)

    12/18/25 4:10:07 PM ET
    $MDCX

    SEC Form 4 filed by Director Rodgers Cathy Mcmorris

    4 - Medicus Pharma Ltd. (0001997296) (Issuer)

    12/18/25 4:09:52 PM ET
    $MDCX

    SEC Form 4 filed by Director Raju Ajay

    4 - Medicus Pharma Ltd. (0001997296) (Issuer)

    12/18/25 4:09:38 PM ET
    $MDCX

    $MDCX
    SEC Filings

    View All

    SEC Form 424B3 filed by Medicus Pharma Ltd.

    424B3 - Medicus Pharma Ltd. (0001997296) (Filer)

    3/6/26 4:58:24 PM ET
    $MDCX

    SEC Form 424B3 filed by Medicus Pharma Ltd.

    424B3 - Medicus Pharma Ltd. (0001997296) (Filer)

    3/6/26 4:57:02 PM ET
    $MDCX

    SEC Form 424B3 filed by Medicus Pharma Ltd.

    424B3 - Medicus Pharma Ltd. (0001997296) (Filer)

    3/6/26 4:55:18 PM ET
    $MDCX

    $MDCX
    Leadership Updates

    Live Leadership Updates

    View All

    Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

    TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

    11/18/24 7:30:00 AM ET
    $GSK
    $MDCX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDCX
    Financials

    Live finance-specific insights

    View All

    Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

    PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce topline results from its Phase 2 clinical study (SKNJCT-003) evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The Company believes the topline results are not only positive but decision-grade that should support an end of phase 2 (EOP2) meeting with the FDA in the first half of 2026 as well as accelerate partnering readiness. S

    3/5/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

    PHILADELPHIA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has received "study may proceed" clearance from the U.S. Food and Drug Administration (FDA) to initiate its Phase 2b dose-optimization study of Teverelix®, an investigational next generation long-acting GnRH antagonist, in men with advanced prostate cancer (APC). Teverelix® Clinical Trial Design in Advanced Prostate Cancer The Phase 2b study is an open-label trial enrolling 40 men with adv

    2/10/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

    Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr) and best in class for prostate cancer patients with high CV risk collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its su

    1/22/26 7:30:00 AM ET
    $MDCX